Intra-Cellular Therapies Retained Earnings (Accumulated Deficit) 2013-2024 | ITCI

Intra-Cellular Therapies retained earnings (accumulated deficit) for the quarter ending September 30, 2024 were $-1.675B, a 5.44% increase year-over-year.

  • Intra-Cellular Therapies retained earnings (accumulated deficit) for 2023 were $-1.617B, a 9.45% increase from 2022.
  • Intra-Cellular Therapies retained earnings (accumulated deficit) for 2022 were $-1.477B, a 20.98% increase from 2021.
  • Intra-Cellular Therapies retained earnings (accumulated deficit) for 2021 were $-1.221B, a 30.32% increase from 2020.

Intra-Cellular Therapies Retained Earnings (Accumulated Deficit) 2013-2024 | ITCI

  • Intra-Cellular Therapies retained earnings (accumulated deficit) for 2023 were $-1.617B, a 9.45% increase from 2022.
  • Intra-Cellular Therapies retained earnings (accumulated deficit) for 2022 were $-1.477B, a 20.98% increase from 2021.
  • Intra-Cellular Therapies retained earnings (accumulated deficit) for 2021 were $-1.221B, a 30.32% increase from 2020.